PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2026ChemistrySelect3 citations

Synthesis, Antimicrobial Activity, and Molecular Docking Studies of New Quinoxaline‐Heterocycle Hybrids

View Full Paper
DADoaa Hassan AliMSMona M. SolimanHDHadeer M. Diab

Key Points

  • The aim is to synthesize and evaluate the antimicrobial properties of new quinoxaline-heterocycle hybrids.
  • Synthesis of bis-heterocyclic hybrids based on a quinoxaline core
  • Characterization using various spectroscopic methods
  • Testing antimicrobial activity against bacterial and fungal strains
  • Molecular docking studies to assess enzyme binding
  • Compound 11 showed the strongest activity against Staphylococcus aureus with an MIC of 1.875 mg/mL
  • Moderate inhibition observed against other strains with MICs up to 7.5 mg/mL
  • Molecular docking revealed strong binding of compound 11 to key bacterial enzymes like glucose oxidase and autolysin

Abstract

ABSTRACT Bacterial infections continue to pose a major global health threat, especially as antimicrobial resistance keeps rising. In this work, we synthesized a series of novel bis‐heterocyclic hybrids built around a quinoxaline core. These compounds came together in good yields and were thoroughly characterized using various spectroscopic methods. We tested their antimicrobial activity against a range of bacterial and fungal strains, and overall, they showed moderate inhibition. Compound 11 stood out as the top performer, knocking down Staphylococcus aureus at an MIC of 1.875 mg/mL, though it was less effective against the others (up to 7.5 mg/mL). To make sense of these results, we ran molecular docking studies, which revealed that compound 11 binds well to key bacterial enzymes involved in virulence and cell‐wall integrity, like glucose oxidase, flavohemoprotein, and autolysin. Even though the activity is still modest, this quinoxaline‐based bis‐heterocycle scaffold looks like a solid foundation for tweaking and boosting potency in future rounds of optimization.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ali et al. (2026) studied this question.

synapsesocial.com/papers/6985859b8f7c464f23009164https://doi.org/10.1002/slct.202506102
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis2024 · 12 citations
  2. 2Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents2024 · 47 citations
  3. 3Quinoxaline: An insight into the recent pharmacological advances2017 · 209 citations
  4. 4Chemical evaluation and antibacterial activity of novel bioactive compounds from endophytic fungi in Nelumbo nucifera2020 · 50 citations
  5. 5Novel α-Cyano-Indolyl Chalcones as Anti-Cancer Candidates, Induce G1/S Cell Cycle Arrest and Sequentially Activate Caspases-7, 8 , and 9 in Breast Carcinoma2024 · 16 citations